Ізраїль - іврит - Ministry of Health

genmedix - activated charcoal 0.2 g/ml - suspension - charcoal preparations - emergency antidote in treatment of poisoning by most drugs and chemicals.

Ізраїль - іврит - Ministry of Health

teva medical marketing ltd. - factor viii human coagulation 250 iu/vial - powder for solution for injection - coagulation factor viii - treatment and prophylaxis of bleeding in patients with congenital (haemophilia a) or acquired factor viii deficiency. von willebrand's disease with factor viii deficiency.

Ізраїль - іврит - Ministry of Health

teva medical marketing ltd. - factor viii human coagulation vhsd treated 500 iu/vial - powder for solution for injection - coagulation factor viii - treatment and prophylaxis of bleeding in patients with congenital (haemophilia a) or acquired factor viii deficiency. von willebrand's disease with factor viii deficiency.

Ізраїль - іврит - Ministry of Health

teva medical marketing ltd. - factor viii human coagulation 1000 iu/vial - powder for solution for injection - coagulation factor viii - treatment and prophylaxis of bleeding in patients with congenital (haemophilia a) or acquired factor viii deficiency. von willebrand's disease with factor viii deficiency.

Ізраїль - іврит - Ministry of Health

inovamed ltd - bicalutamide - טבליות מצופות פילם - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0), bicalutamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable

Ізраїль - іврит - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

Ізраїль - іврит - Ministry of Health

"a.m.i. technologies, ltd." - רופא - טיפול קוסמטי ע'י גלי רדיו

Ізраїль - іврит - Ministry of Health

m.t.r.e advanced technologies ltd. - אחות

Ізраїль - іврит - Ministry of Health

m.t.r.e advanced technologies ltd. - אחות

Ізраїль - іврит - Ministry of Health

nim ltd. - רופא - אקדח לביופסיה לרקמות רכות ומחטי מעבר לביופסיה